Enovis launches CT-RevitL to enhance veterinary pain management and boost investor confidence

Enovis has introduced the CT-RevitL, a veterinary photobiomodulation laser system with intelligent guidance features, aiming to improve clinical outcomes and support long-term growth amid investor pressures.

Enovis has rolled out CT-RevitL in the US, a new veterinary photobiomodulation laser system from its Companion Animal Health arm, aiming to make pain relief and recovery support easier to deliver in day-to-day practice. The company says the device is designed to improve performance, mobility and usability for veterinary teams. It also brings in COMPASS, an intelligent guidance feature intended to standardise dosing and reduce variation between users.

For veterinarians, the appeal is practical as much as clinical. According to Enovis, laser therapy is already used for pain control, tissue healing, inflammation and post-operative recovery across musculoskeletal and soft-tissue cases. The company says the launch is backed by clinical education and specialist support, with the system now available to practices across the US and overseas availability to follow later.

The broader commercial question is whether the product can help lift a business that investors still see as dependent on better margins and cleaner execution. Simply Wall St notes that Enovis remains under pressure to convert heavy investment and acquisition integration into steadier profits, with its next earnings update on 6 August likely to matter more than any single product release. The article also points to long-term revenue and earnings growth hopes that depend on launches such as CT-RevitL gaining traction.

Image Source: Enovis